| Name | Title | Contact Details |
|---|
Acris Antibodies is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
InnovaPrep is engaged in product development, manufacturing, sales, service, and related out-licensing of a collection of novel technologies enabling rapid detection of biological particles and pathogens. Our core business is biological sample collection, concentration and preparation. The company has commercialized a collection of market-disruptive platform technologies for rapid, automated concentration of biological particles. InnovaPrep`s 35 pending and awarded patents apply to highly efficient collection, recovery, and concentration of biological particles from air, surfaces, and liquids. Our elution process underlies many of these patents and enables recovery of particles from filters, membranes, surfaces, and objects. The primary utility for these technologies is to greatly improve the way biological samples, especially those containing pathogenic organisms, are collected and prepared for analysis beyond the state-of-the-art. These technologies fill a critical void that currently severely limits application of the most advanced biological detection systems to the billions of microbiological tests performed annually. Markets served: Biodefense, food safety, water safety, biopharma, clinical research, animal health, environmental monitoring and others.
With offices in Philadephia and Boston, SwanBio Therapeutics is developing leading-edge therapies to deliver dramatic clinical efficacy for the treatment of neurological diseases. We are driven by an unrelenting passion to solve difficult challenges, and a belief that meaningful discovery is borne of curiosity, collaboration, and compassion. Founded by proven industry leaders with a commitment to positively impacting the lives of people with neurological diseases, SwanBio merges clinical, scientific and drug commercialization expertise.
Rgenta Therapeutics is developing a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology and neurological disorders. Our proprietary platform mines the massive genomics data to identify targetable RNA processing events and design small-molecule glues to modulate the interactions among the spliceosome, regulatory proteins, and RNAs
Bayer and CRISPR Therapeutics have entered into an agreement to create Casebia to discover, develop and commercialize new breakthrough therapeutics to cure blood disorders, blindness, and congenital heart disease. CRISPR Therapeutics will contribute its proprietary CRISPR-Cas9 gene-editing technology and intellectual property, while Bayer will make available its protein engineering expertise and relevant disease know-how. It is the first long-term strategic partnership of its kind to make a substantial investment in the development of target delivery systems in an effort to bring systemic in vivo CRISPR-Cas9 gene editing technology applications to patients.